Tango Therapeutics, Inc. Operating Cash Flow
Tango Therapeutics, Inc. (TNGX) reported Operating Cash Flow of -$83.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$38.87M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$44.36M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$29.72M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.95M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$138.89M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$131.50M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$117.98M.
- Tango Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$109.08M.
| Period end | Net Cash Provided by (Used in) Operating Activities 1 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 4 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 7 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$38.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$83.23M 10-Q · filed 2026-08-11 | -$112.94M derived: sum of 3 quarters · filed 2026-08-11 | -$143.90M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2026-03-31 | -$44.36M 10-Q · filed 2026-05-13 | -$74.08M derived: sum of 2 quarters · filed 2026-05-13 | -$105.03M derived: sum of 3 quarters · filed 2026-05-13 | -$141.55M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-12-31 | -$29.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$60.67M derived: sum of 2 quarters · filed 2026-03-05 | -$97.19M derived: sum of 3 quarters · filed 2026-08-11 | -$138.89M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | -$30.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$67.47M derived: sum of 2 quarters · filed 2026-08-11 | -$109.17M 10-Q · filed 2025-11-04 | -$145.81M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-06-30 | -$36.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$78.22M 10-Q · filed 2026-08-11 | -$114.86M derived: sum of 3 quarters · filed 2026-08-11 | -$148.25M derived: sum of 4 quarters · filed 2026-08-11 | |||||
| 2025-03-31 | -$41.70M 10-Q · filed 2026-05-13 | -$78.34M derived: sum of 2 quarters · filed 2026-05-13 | -$111.73M derived: sum of 3 quarters · filed 2026-05-13 | -$135.34M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | -$36.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$70.04M derived: sum of 2 quarters · filed 2026-03-05 | -$93.64M derived: sum of 3 quarters · filed 2026-03-05 | -$131.50M 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | -$33.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$57.00M derived: sum of 2 quarters · filed 2025-11-04 | -$94.85M 10-Q · filed 2025-11-04 | -$122.32M derived: sum of 4 quarters · filed 2026-03-05 | |||||
| 2024-06-30 | -$23.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$61.46M 10-Q · filed 2025-08-05 | -$88.93M derived: sum of 3 quarters · filed 2026-03-05 | -$120.07M derived: sum of 4 quarters · filed 2026-03-05 | |||||
| 2024-03-31 | -$37.86M 10-Q · filed 2025-05-12 | -$65.32M derived: sum of 2 quarters · filed 2026-03-05 | -$96.46M derived: sum of 3 quarters · filed 2026-03-05 | -$120.93M derived: sum of 4 quarters · filed 2026-03-05 | |||||
| 2023-12-31 | -$27.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$58.60M derived: sum of 2 quarters · filed 2026-03-05 | -$83.08M derived: sum of 3 quarters · filed 2026-03-05 | -$117.98M 10-K · filed 2026-03-05 | |||||
| 2023-09-30 | -$31.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$55.61M derived: sum of 2 quarters · filed 2024-11-06 | -$90.52M 10-Q · filed 2024-11-06 | -$118.78M derived: sum of 4 quarters · filed 2025-02-27 | |||||
| 2023-06-30 | -$24.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$59.38M 10-Q · filed 2024-08-07 | -$87.65M derived: sum of 3 quarters · filed 2025-02-27 | -$107.26M derived: sum of 4 quarters · filed 2025-02-27 | |||||
| 2023-03-31 | -$34.91M 10-Q · filed 2024-05-08 | -$63.17M derived: sum of 2 quarters · filed 2025-02-27 | -$82.78M derived: sum of 3 quarters · filed 2025-02-27 | -$114.32M derived: sum of 4 quarters · filed 2025-02-27 | |||||
| 2022-12-31 | -$28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$47.88M derived: sum of 2 quarters · filed 2025-02-27 | -$79.42M derived: sum of 3 quarters · filed 2025-02-27 | -$109.08M 10-K · filed 2025-02-27 | |||||
| 2022-09-30 | -$19.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$51.15M derived: sum of 2 quarters · filed 2023-11-08 | -$80.81M 10-Q · filed 2023-11-08 | -$97.72M derived: sum of 4 quarters · filed 2023-11-08 | |||||
| 2022-06-30 | -$31.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$61.20M 10-Q · filed 2023-08-07 | -$78.11M derived: sum of 3 quarters · filed 2023-08-07 | -$99.60M derived: sum of 4 quarters · filed 2023-08-07 | |||||
| 2022-03-31 | -$29.66M 10-Q · filed 2023-05-09 | -$46.57M derived: sum of 2 quarters · filed 2023-05-09 | -$68.06M derived: sum of 3 quarters · filed 2023-05-09 | -$75.58M derived: sum of 4 quarters · filed 2023-05-09 | |||||
| 2021-12-31 | -$16.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$38.40M derived: sum of 2 quarters · filed 2023-03-27 | -$45.91M derived: sum of 3 quarters · filed 2023-03-27 | -$59.53M 10-K · filed 2023-03-27 | |||||
| 2021-09-30 | -$21.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$29.01M derived: sum of 2 quarters · filed 2022-11-10 | -$42.63M 10-Q · filed 2022-11-10 | -$60.69M derived: sum of 4 quarters · filed 2022-11-10 | |||||
| 2021-06-30 | -$7.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$21.13M 10-Q · filed 2022-08-10 | -$763.66K 10-Q · filed 2021-08-09 | -$39.19M derived: sum of 3 quarters · filed 2022-08-10 | |||||
| 2021-03-31 | -$13.61M 10-Q · filed 2022-05-11 | -$55.63K 10-Q · filed 2021-05-14 | -$31.68M derived: sum of 2 quarters · filed 2022-05-11 | ||||||
| 2020-12-31 | -$18.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$327.42K 10-K · filed 2021-03-31 | $70.07M 10-K · filed 2022-03-28 | ||||||
| 2020-09-30 | -$89.28K 10-Q · filed 2020-11-13 | $88.14M 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | -$32.00 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |